Upadacitinib for previously treated moderate active rheumatoid arthritis: Appraisal consultation 2

DRAFT guidance does not recommend upadacitinib with or without methotrexate for treating moderate active rheumatoid arthritis (DAS28 of 3.2 to 5.1) in adults who cannot tolerate, or whose disease has responded inadequately to ≥1 conventional DMARDs.

Source:

National Institute for Health and Care Excellence